Description Spirochete bacterium that causes Lyme borreliosis (Lyme disease)
Structure Borrelia burgdorferi is a Gram-negative, highly motile spirochete belonging to the Borrelia burgdorferi sensu lato complex and the family Spirochaetaceae. The bacterium possesses a distinctive helical morphology and periplasmic flagella that enable corkscrew-like movement through host tissues and extracellular matrices. Borrelia burgdorferi is transmitted primarily through the bite of infected Ixodes ticks, including Ixodes scapularis and Ixodes pacificus in North America. The organism is maintained in nature through complex transmission cycles involving ticks and reservoir hosts such as rodents, birds, and other small mammals. Following inoculation into the skin, B. burgdorferi can disseminate through the bloodstream and lymphatic system to multiple organs, including the joints, heart, skin, and nervous system. It is the principal causative agent of Lyme disease in North America and one of the most extensively studied tick-borne bacterial pathogens.
Diagnosis The diagnosis of Borrelia burgdorferi infection is performed through a combination of clinical assessment, serological testing, and molecular methods. Laboratory diagnosis typically follows a two-tier testing strategy consisting of an initial ELISA or immunoassay followed by confirmatory immunoblot testing when appropriate. Detection of Borrelia-specific IgM and IgG antibodies provides evidence of infection, although antibody responses may not be detectable during the earliest stages of disease. Polymerase chain reaction (PCR) assays may be used to detect Borrelia DNA in synovial fluid, skin biopsies, cerebrospinal fluid, and other clinical specimens. Clinical findings, exposure history, and laboratory results are interpreted together because no single diagnostic test is sufficient in all stages of disease. Early diagnosis is important because prompt antimicrobial treatment can prevent progression to disseminated infection.
Symptoms Borrelia burgdorferi infection typically begins with localized Lyme disease following the bite of an infected tick. The most characteristic early manifestation is erythema migrans, an expanding skin lesion that develops days to weeks after exposure and may be accompanied by fever, fatigue, headache, muscle aches, and joint pain. If untreated, the infection may disseminate and involve multiple organ systems. Neurological manifestations can include meningitis, facial nerve palsy, radiculoneuritis, and peripheral neuropathy. Cardiac involvement may result in Lyme carditis with conduction abnormalities and arrhythmias. Late-stage disease commonly presents with intermittent or persistent arthritis, particularly affecting large joints such as the knee. Some patients may experience prolonged fatigue, musculoskeletal discomfort, and cognitive symptoms following treatment, although the mechanisms underlying these persistent symptoms remain an area of ongoing investigation.
Data
FAQ & Publications
Frequently Asked Questions
What is the intended application of the Borrelia burgdorferi IgM Control Serum BC121M?
The Borrelia burgdorferi IgM Control Serum BC121M is intended for use as a control serum in ELISA assays, specifically for indirect and quantitative detection of Borrelia burgdorferi reactive IgM antibodies.
How should the Borrelia burgdorferi IgM Control Serum BC121M be stored to maintain stability?
This control serum should be stored at 2-8°C to preserve its stability and ensure reliable performance in assays.
Is the Borrelia burgdorferi IgM Control Serum BC121M compatible with specific ELISA kits?
Yes, the serum is ready-to-use and pre-diluted for compatibility with SERION ELISA classic and SERION ELISA antigen assays targeting Borrelia burgdorferi IgM.
Which species and target does the Borrelia burgdorferi IgM Control Serum BC121M specifically react with?
The control serum specifically reacts with IgM antibodies against Borrelia burgdorferi, the bacterial species responsible for Lyme disease.
Publications
pmid
title
authors
citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.